Tobacco Cessation Interventions With Ohio Appalachian Smokers

Status Completed

Clinical Trial Summary

Tobacco use remains a significant public health problem and is increasingly prevalent among vulnerable groups. Appalachians have a high prevalence of tobacco use and are at increased risk for tobacco-attributable diseases. The efficacy of a scientifically valid tobacco cessation treatment delivered to Appalachian smokers remains untested. Also, little is known about the association of social-contextual factors that may modify or mediate the success of an intervention. These factors may be of particular relevance among disadvantaged smokers. Geographical patterns of tobacco exposure may also influence one's ability to quit, especially in pro- tobacco regions like Appalachia. The purposes of this application are to: 1) evaluate the efficacy of a lay-led (LL) intervention in promoting long term abstinence from tobacco; and 2) examine the association between 12 month abstinence and selected individual, interpersonal, organizational, neighborhood and community, and societal factors among adult Appalachian tobacco users exposed to a tobacco cessation intervention. A third aim is exploratory and includes the characterization of activity patterns using space-time measures among adult Appalachian tobacco users exposed to a tobacco cessation intervention. Using a group randomized trial design, 707 Appalachian residents from 6 intervention and 6 control counties will be randomly assigned by county to receive the LL intervention or a control condition which includes proactive telephone counseling via the Ohio Quit Line. LL group participants will receive face-to-face counseling, supervised by a county health department nurse, and delivered by a trained lay educator. A county Extension agent will assist with recruitment and retention efforts in this project. Social-contextual factors will be assessed at a baseline interview administered to all participants. Space-time activity geographical patterns of pro- and anti-tobacco exposures, or features, will be described among selected participants in four counties during weeks 1, 6 and 12 of treatment. At end of treatment and 6 and 12 months, LL and control group participants will be reassessed for tobacco use via self-report and cotinine-validation. Secondary analyses will explore differential trends over time between the two arms of the study. In a subset of the sample, pro- and anti-tobacco exposures will be estimated during weeks 1, 6 and 12 of treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02695225
Study type	Interventional
Source	Ohio State University
Contact
Status	Completed
Phase	N/A
Start date	November 2010
Completion date	October 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01928719` - Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status	N/A
Completed	`NCT01995123` - Behavioral Activation for Smoking Cessation in PTSD	N/A
Not yet recruiting	`NCT03249428` - E-Cigarette Inner City RCT	N/A
Recruiting	`NCT02564289` - Cardiovascular Effects of Chronic Snus Use	N/A
Completed	`NCT01928758` - Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders	N/A
Withdrawn	`NCT01847300` - cSBI-M for Young Military Personnel	N/A
Completed	`NCT01570595` - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV	Phase 1/Phase 2
Completed	`NCT01428310` - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke	Phase 1
Recruiting	`NCT00977249` - Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users	Phase 2/Phase 3
Active, not recruiting	`NCT00968513` - Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry	Phase 3
Completed	`NCT00722124` - S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence	Phase 2/Phase 3
Completed	`NCT00747643` - Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement	N/A
Completed	`NCT01113424` - Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum	N/A
Completed	`NCT01238627` - Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg	N/A
Completed	`NCT01228617` - Single-dose Pharmacokinetics of Oral Nicotine Replacement Products	N/A
Completed	`NCT00296647` - Smoking Cessation Intervention: Effectiveness in Primary Care	Phase 4
Completed	`NCT00394420` - Emergency Department Telephone Quitline	N/A
Recruiting	`NCT05487807` - Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia	Phase 1
Completed	`NCT03553992` - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers	N/A
Withdrawn	`NCT05440721` - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.